Morgan Stanley Maintains Equal-Weight on Vicarious Surgical, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on Vicarious Surgical (NYSE:RBOT) but lowers the price target from $18 to $10.
July 15, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Vicarious Surgical but has significantly lowered the price target from $18 to $10.
The significant reduction in the price target from $18 to $10 by a major financial institution like Morgan Stanley is likely to negatively impact investor sentiment and the short-term stock price of Vicarious Surgical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100